Sodium-glucose cotransporter 2 inhibitors (SGLT-2i), initially developed for managing type 2 diabetes mellitus (T2DM), have garnered significant attention for their multifaceted therapeutic benefits extending beyond glycemic control (1). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.